Value proposition

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH).

In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.

Our corporate headquarters is located in New Jersey.

For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

Non-viral Liver Diseases, Rare Diseases, Biotechnology, and Innovation